CD274 and neoplasm: One study using neoadjuvant pembrolizumab to treat recurrent GBM (11) or expression of PD-L1 by the tumor (12) improved the median survival to 13.7 and 13.1 months, respectively, compared with historical controls using lomustine combined with bevacizumab (2).